Selegiline's neuroprotective capacity revisited

J Neural Transm (Vienna). 2003 Nov;110(11):1273-8. doi: 10.1007/s00702-003-0083-x.
No abstract available

Publication types

  • Comment
  • Meta-Analysis

MeSH terms

  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use*
  • Brain / drug effects
  • Brain / enzymology
  • Clinical Trials as Topic / statistics & numerical data
  • Drug Therapy, Combination
  • Humans
  • Monoamine Oxidase / drug effects
  • Monoamine Oxidase / metabolism
  • Monoamine Oxidase Inhibitors / pharmacology
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Multicenter Studies as Topic / statistics & numerical data
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Selegiline / pharmacology
  • Selegiline / therapeutic use*

Substances

  • Antiparkinson Agents
  • Monoamine Oxidase Inhibitors
  • Neuroprotective Agents
  • Selegiline
  • Monoamine Oxidase